MedTrace Logo

The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

NCT00599222 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-11-22

No results posted yet for this study

Summary

Neovascular age-related macular degeneration (AMD) is the leading cause of severe vision loss in the Western world. Intravitreal ranibizumab has recently become the treatment of choice for neovascular (AMD). Limitations to ranibizumab however include the high cost for the drug and the need for frequent intravitreal re-injections. The investigators' hypothesis is that when ranibizumab is combined with transpupillary thermotherapy (TTT) the number of necessary retreatments with Lucentis will be significantly reduced as compared to ranibizumab alone.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

ranibizumab

0.5 mg intravitreal injection

PROCEDURE

TTT

Transpupillary thermotherapy (TTT)

PROCEDURE

Sham TTT

Sham Transpupillary thermotherapy (TTT)

Sponsors & Collaborators

  • Anders Kvanta

    lead OTHER

Principal Investigators

  • Anders Kvanta · St Eriks Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-11-30
Completion
2010-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599222 on ClinicalTrials.gov